U.S. Biotech with 7 Trillion Won Riding on Huntington's Disease New Drug Data

PTC Therapeutics Inc. (NASDAQ: PTCT) closed yesterday on the Nasdaq at $65.15—up 0.14%—equivalent to roughly ₩88,000. Its market capitalization rose by about $7.57 million (approximately ₩10 billion) to around $5.4 billion (about ₩7 trillion).

The company recently released 24-month interim data from the long-term PIVOT-HD extension study of Votoplam, its oral candidate for Huntington’s disease, showing that high doses slowed disease progression by roughly 52%, which bolstered investor sentiment. The Q1 2026 earnings report, due after market close on May 7, is also expected to be a key catalyst for share-price volatility.

PTC Therapeutics is a U.S. biotech firm developing oral small molecules and gene therapies that regulate gene expression to treat rare and genetic disorders. It has secured both pipeline and royalty revenues from products such as Translarna for Duchenne muscular dystrophy and Evrysdi for spinal muscular atrophy, and is positioning Votoplam as its next growth driver.